// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.

Andrew Jehyun Song - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

Temozolomide

Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS) of patients with metastatic cancer.

Atul Batra - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.

Muna Qayed - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fragility index of trials supporting approval of anti-cancer drugs in common solid tumors.

Alexandra Desnoyers - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Comprehensive next-generation profiling of clonal hematopoiesis in cancer patients using paired tumor-blood sequencing for guiding personalized therapies.

Ziyang Li - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN.

Fred Saad - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

New insights in the pharmacotherapy of psychosis: The example of Parkinson's disease psychosis

A.Fontaine - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Pimavanserin

The use of patient health information outside the circle of care: Consent preferences of patients from a large academic cancer centre.

Fei Fei Liu - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Syrian refugees in Canada: Clinical experience in mental health care

K.Bazaid - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Task-shifting in mental health services: Extent, impact and challenges in Ghana

V.Agyapong - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Peter C. Black - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Atezolizumab

Adapting the assertive community treatment (ACT) for the needs of different communities: A comparative case study of KUINA ACT Japan and Mt. Sinai ACT Canada

W.Chow - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Adult ADHD and the use of mindfulness-based practice: A pilot study

A.Allen - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Clinical analysis of the extracellular vesicle-fingerprint score blood test to refine the prediction of clinically significant prostate cancer and avoid prostate biopsy.

Adrian S. Fairey - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

hGH

Symptom burden as a predictor of emergency room use and unplanned hospitalization in patients with head and neck cancer: A population-based study.

Christopher Noel - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

The impact of first-line therapy with novel agents in multiple myeloma patients age 80 and above: A systematic review.

Sadaf Rahman - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.

Adam D. Cohen - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

GSK2857916

What is commonly missed in the suicidal risk assessments in the emergency room?

N.Alavi - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methadone hydrochloride

Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.

Lucy Xiaolu Ma - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

ECOG-ACRIN tomosynthesis mammographic imaging screening trial (EA1151).

Etta Pisano - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved